Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant modelVincent Faugeroux(Centre National de la Recherche Scientifique), Françoise Farace(Institut Gustave Roussy)Nature CommunicationsApril 20, 202010.1038/s41467-020-15426-2Cited by 80SaveCiteExport RISWatch citationsRelated PapersEfficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma|The Oncologist|2012|132Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants|JCI Insight|2022|43Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study|Oncotarget|2016|36Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors|Cancer Research|2008|8